Clinical Note: The FSFI is a multi-dimensional assessment. Total score ≤ 26.55 is the standard clinical threshold for identifying women with female sexual dysfunction.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
Primary Clinical Uses
Baseline assessment and screening tool for identifying Female Sexual Dysfunction (FSD)
Measuring therapeutic efficacy of interventions (e.g., localized estrogen, ospemifene, flibanserin)
Research standard for quantifying multidimensional sexual function in clinical trials
What it Measures
The FSFI is uniquely potent because it disaggregates sexual function into 6 distinct physical and psychological domains over the past 4 weeks: Desire, Arousal, Lubrication, Orgasm, Satisfaction, and Pain.
Section 2
Formula & Logic
Scoring Breakdown
The index consists of 19 questions. Each response is scaled, multiplied by a specific domain factor. The maximum total score is 36. Higher scores equal better function.
Clinical Threshold
> 26.55
Normal sexual function
≤ 26.55
Highly suggestive of Female Sexual Dysfunction (FSD)
Section 3
Pearls/Pitfalls
Critical Caveats
A low score does NOT automatically mean the patient is distressed. By definition, FSD or Hypoactive Sexual Desire Disorder (HSDD) requires the symptoms to cause profound personal distress. If they score a 15 but are perfectly happy, there is no disorder to treat.
The tool inherently relies on sexual activity within the last 4 weeks. If the patient has been entirely abstinent, the scores artificially zero out.
It does not diagnose the etiology. It cannot distinguish between SSRI-induced anorgasmia vs. profound marital discord vs. menopausal vaginal atrophy.
Section 4
Next Steps
Management via Exact Subdomains
01
Isolate the driving domain: Look at which of the 6 areas failed the worst.
02
Pain/Lubrication Predominant: Suspect Genitourinary Syndrome of Menopause (GSM), vestibulodynia, or endometriosis. Treat first with vaginal moisturizers, escalating to topical vaginal estradiol or DHEA.
03
Desire/Arousal Predominant: Evaluate medications (SSRIs/SNRIs, beta blockers), thyroid function, and relationship factors. Consider centrally acting agents (flibanserin/bremelanotide) if premenopausal HSDD is diagnosed.
The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function.
Rosen R et al. • J Sex Marital Ther.. 2000;The foundational publication which introduced the 19-item questionnaire and established its high internal reliability and validity.
The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores.
Wiegel M et al. • J Sex Marital Ther.. 2005;The study that calculated the mathematically optimal cutoff score of 26.55 for differentiating women with vs. without clinical sexual dysfunction.
Section 6
Literature
Context
Prior to the year 2000, female sexual function research was remarkably sparse and unstructured compared to men (where the IIEF dominated). Dr. Raymond Rosen and colleagues developed the FSFI to fill this immense void, ultimately standardizing the entire field of female sexual medicine.
